TAK 935

Drug Profile

TAK 935

Alternative Names: OV 935; TAK935

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer Ovid Therapeutics; Takeda
  • Class Heterocyclic compounds; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Cholesterol 24-hydroxylase inhibitors; NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dravet syndrome; Lennox-Gastaut syndrome; Tuberous sclerosis
  • Phase I Epilepsy

Most Recent Events

  • 13 Jun 2017 Phase-II clinical trials in Dravet syndrome, Lennox-Gastaut syndrome and Tuberous sclerosis (rare epileptic encephalopathies) (Adjunctive treatment) in USA (PO) (NCT03166215)
  • 31 May 2017 Takeda and Ovid plan a phase II trial for Dravet syndrome, Lennox-Gastaut syndrome and Tuberous Sclerosis (Epileptic encephalopathies) (Adjunctive therapy) (PO, Tablet) (NCT03166215)
  • 18 Jan 2017 Takeda Pharmaceutical and Ovid Therapeutics collaborate for the development and commercialisation of TAK 935
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top